Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Pandion Therapeutics, Inc. (PAND)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/01/2021 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 02/25/2021 |
8-K
| Quarterly results |
| 01/04/2021 |
8-K
| Quarterly results |
| 12/03/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Pandion Therapeutics Appoints Katina Dorton to its Board of Directors WATERTOWN, Mass. - December 3, 2020 - Pandion Therapeutics, Inc. , a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion's board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company's board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expertise, leading a multitude of financial transactions for comp..." |
|
| 11/16/2020 |
8-K
| Quarterly results |
| 08/31/2020 |
8-K
| Quarterly results |
| 07/21/2020 |
8-K
| Quarterly results |
|
|